Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OrthoLogic completes dosing in Phase I dermal scarring trial
The safety committee reviewing all safety-related aspects of the clinical trial was satisfied with the profile of AZX100. On this basis, OrthoLogic plans to initiate its next Phase
The safety committee reviewing all safety-related aspects of the clinical trial was satisfied with the profile of AZX100. On this basis, OrthoLogic plans to initiate its next Phase
Under the expanded access program, children two months to 17 years in age inclusive with grades B-D graft versus host disease (GvHD) not responsive to steroids are eligible
Safety and tolerability of orally administered ENMD-2076 in refractory cancer patients will be assessed in this Phase I study. A secondary objective for the study will be to
The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to
The option, which was obtained through negotiation with the Harvard University’s Office of Technology Development, encompasses an issued US patent that covers engineered variants of protective antigen (PA)
According to Michael Beckert, chief medical officer of LifeCycle Pharma, the Phase II clinical program confirmed that LCP-AtorFen was safe and well-tolerated. In addition, the study showed significantly
NKTR-118 was also shown to be safe and generally well-tolerated at doses up to 250mg twice daily, with no serious or severe adverse events. The pharmacokinetics of NKTR-118
The results demonstrated that mice treated with a soluble form of the ActRIIA receptor increases trabecular bone volume by 45%, 120%, 130% and 248% compared to untreated animals
Pursuant to the settlement and release agreement among Alphatec and DePuy & Biedermann, Alphatec has obtained a license to intellectual property rights owned by Biedermann and licensed to
Cadence’s confirmatory Phase III clinical trial of Omigard (omiganan pentahydrochloride 1% gel), known as the Central Line Infection Reduction Study (CLIRS), is a randomized, evaluator-blinded study in hospitalized